Product NDC: | 49288-0183 |
Proprietary Name: | Dock/Sorrel Mixture |
Non Proprietary Name: | Dock/Sorrel Mixture |
Active Ingredient(s): | .025; .025 g/mL; g/mL & nbsp; Dock/Sorrel Mixture |
Administration Route(s): | INTRADERMAL; SUBCUTANEOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 49288-0183 |
Labeler Name: | Antigen Laboratories, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | BLA102223 |
Marketing Category: | BLA |
Start Marketing Date: | 20070716 |
Package NDC: | 49288-0183-5 |
Package Description: | 50 mL in 1 VIAL, MULTI-DOSE (49288-0183-5) |
NDC Code | 49288-0183-5 |
Proprietary Name | Dock/Sorrel Mixture |
Package Description | 50 mL in 1 VIAL, MULTI-DOSE (49288-0183-5) |
Product NDC | 49288-0183 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Dock/Sorrel Mixture |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRADERMAL; SUBCUTANEOUS |
Start Marketing Date | 20070716 |
Marketing Category Name | BLA |
Labeler Name | Antigen Laboratories, Inc. |
Substance Name | RUMEX ACETOSELLA POLLEN; RUMEX CRISPUS POLLEN |
Strength Number | .025; .025 |
Strength Unit | g/mL; g/mL |
Pharmaceutical Classes | Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Pollen Allergenic Extract [EPC],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Increased Histamine Release [PE],Allergens [Chemical/Ingredient] |